Related Experiment Video
Updated: May 29, 2026

Using a Bacterial Pathogen to Probe for Cellular and Organismic-level Host Responses
Published on: February 22, 2019
Short-term gentamicin therapy and risk of renal toxicity in patients with bacteraemia
Marianne H Spanggaard1, Bo L Hønge, Henrik C Schønheyder
1Department of Infectious Diseases, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.
Abstract:
The renal safety of gentamicin has been questioned even when dosed once daily. This retrospective cohort study comprised adult patients with community-acquired bacteraemia and no record of chronic renal disease or malignancy. We included patients treated with gentamicin once daily for ≤ 5 days (165 exposed patients) and a balanced sample of patients not receiving aminoglycosides (150 non-exposed patients). The primary endpoint, which was an elevation in plasma creatinine of > 40 μmol/l from baseline, was equally common among exposed (7.9%) and non-exposed patients (8.7%) (p = 0.80). Among 26 patients with the primary endpoint, follow-up creatinine levels were evaluable in 21 patients and reached the normal range in 8/12 (67%) exposed patients and in 7/9 (78%) non-exposed patients (p = 0.66). Thirty-day mortality was 7.9% in exposed patients versus 7.3% in non-exposed patients (p = 0.86). We conclude that renal impairment in bacteraemic patients is independent of short-term (≤ 5 days) gentamicin administration.
Insights
Short-term gentamicin (≤ 5 days) administration did not increase renal impairment risk in patients with community-acquired bacteremia. Renal safety was similar between gentamicin-exposed and non-exposed groups, indicating no significant difference in kidney function.
Area of Science:
- Nephrology
- Infectious Diseases
- Pharmacology
Background:
- Gentamicin's renal safety is a concern, particularly with once-daily dosing.
- Previous studies have raised questions about potential kidney damage from gentamicin.
Purpose of the Study:
- To evaluate the renal safety of short-term, once-daily gentamicin in adult patients with community-acquired bacteremia.
- To compare the incidence of renal impairment between gentamicin-exposed and non-exposed patient groups.
Main Methods:
- Retrospective cohort study of adult patients with community-acquired bacteremia.
- Inclusion criteria: no chronic renal disease or malignancy, gentamicin treatment ≤ 5 days (n=165) or no aminoglycosides (n=150).
- Primary endpoint: plasma creatinine elevation > 40 μmol/l from baseline; secondary endpoint: 30-day mortality.
Main Results:
- Elevated creatinine occurred in 7.9% of gentamicin-exposed patients versus 8.7% of non-exposed patients (p=0.80).
- Follow-up creatinine normalized in 67% of exposed and 78% of non-exposed patients with elevated creatinine (p=0.66).
- 30-day mortality was 7.9% for exposed and 7.3% for non-exposed patients (p=0.86).
Conclusions:
- Short-term (≤ 5 days) gentamicin administration is not associated with increased renal impairment in bacteremic patients.
- Renal impairment in this context appears independent of gentamicin use.
- Gentamicin can be considered safe for short-term use in this patient population regarding renal function.
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Estimation of k and VD of Aminoglycosides
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Inhibitors of Bacterial Protein Synthesis
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
